Press release
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
– Net product sales of $121.4 million, a 23% increase over same quarter of prior year – CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta
About this update from Sarepta Therapeutics, Inc.
[{"type":"text","content":"– Net product sales of $121.4 million, a 23% increase over same quarter of prior year –\n CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2020. “Even as the pandemic created challenges throughout the third quarter, I am pleased to report that the Sarepta team was able to continue to serve the Duchenne muscular dystrophy community with little interruption, achieving net product revenue of $121.4 million for EXONDYS 51 (eteplirsen) and VYONDYS 53 (golodirsen), representing a 23% increase over the same quarter last year,” said Doug Ingram, Sarepta’s president and CEO. “At the same time, we advanced our RNA pipeline with a filing of and the FDA’s acceptance of the NDA for our next PMO candidate, casimersen, and prepared our next-generation candidate, the peptide-conjugated PMO, SRP-5051 for a data readout by the end of 2020. We also announced, at the World Muscle Society congress, positive data for SRP-9001 and SRP-9003, two critical drivers of our first-in-class gene therapy engine, and in support of these programs continued to build our strength in manufacturing. As we reported in a separate release today, the FDA has agreed on an approach for a potency assay which should permit us to dose patients with commercial process material in Study SRP-9001-103, an important milestone in our goal of bringing a potentially profound therapy to a waiting Duchenne community.” Third Quarter 2020 and Recent Corporate Developments: Announced positive 2-year functional data of SRP-9001 micro-dystrophin gene therapy in Duchenne muscular dystrophy (DMD) patients: The clinical results, presented at the 25th International Annual Congress of the World Muscle Society (WMS), demonstrated that two years after a one-time infusion of SRP-9001, trial participants exhibited a mean 7.0 point improvement on the North Star Ambulatory Assessment (NSAA) compared to baseline (at one year post treatment the mean increase was 5.5 points from baseline). NSAA is a validated scale developed to measure functional motor abilities in ambulant children with DMD. The data were generated from four ambulatory participants, ages 4 to 7, in Sarepta’s open-label trial, Study 101, and showed continued safety and tolerab...